Andrle Edward 4

What Happened
Edward Andrle, a director of NeuroOne Medical Technologies Corp (NMTC), received two equity awards on 2026-04-03: 41,929 shares reported as an award (restricted stock units) and 26,036 shares reported as a derivative award (an option-like grant). Both were reported at $0.00 per share (no cash paid) and are structured to vest over a one-year period in 12 equal monthly installments, so the shares are not immediately freely tradable.

Key Details

• Transaction date: 2026-04-03; Filing date: 2026-04-07. (Form 4 filed four days after the transaction; Form 4s are generally due within two business days — check trading-day timing if timing is a concern.)
• Awards: 41,929 RSUs (code A) and 26,036 derivative/option-based shares (code A), both at $0.00, total reported acquisition value $0.
• Vesting: RSUs vest in 12 equal monthly installments over one year (Footnote F1). The derivative/option vests in 12 equal monthly installments over one year (Footnote F2).
• Shares owned after transaction: Not specified in the provided summary of the filing.
• No 10b5-1 plan, tax-withholding sale, or immediate sale noted in the reported items.

Context
These are grants/awards, not open-market purchases or sales. Because the awards vest over time, they do not represent immediate insider buying of freely tradable shares and therefore are less directly informative about near-term insider market sentiment than outright purchases. Derivative grants (options) typically require vesting before any exercise or sale can occur.